EGFR tyrosine kinase inhibitor AG1478 inhibits cell proliferation and arrests cell cycle in nasopharyngeal carcinoma cells

被引:105
作者
Zhu, XF
Liu, ZC
Xie, BF
Li, ZM
Feng, GK
Yang, DJ
Zeng, YX
机构
[1] Sun Yat Sen Univ Med Sci, Ctr Canc, Inst Canc, Guangzhou 510060, Peoples R China
[2] Georgetown Univ, Lombardi Canc Ctr, Washington, DC 20007 USA
关键词
nasopharyngeal carcinoma; EGFR; AG1478; cell cycle; cell proliferation;
D O I
10.1016/S0304-3835(01)00547-X
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Nasopharyngeal carcinoma (NPC), which occurs with a high incidence in southern China and southeast Asia, is of epithelial origin with overexpression of EGF receptor. To study the effect of inhibition of EGFR signaling on nasopharyngeal carcinoma cell proliferation and cell cycle distribution, EGFR tyrosine kinase inhibitor AG1478 was employed to treat Nasopharyngeal Carcinoma CNE2 cells. The results showed that AG1478 inhibited proliferation of CNE2 cells. Immunoblot showed that AG1478 inhibited EGER phosphorylation in CNE2 cells without reduced expression of EGFR protein. The activation of Akt and MAPK which are downstream molecules of EGFR signaling pathway, were also inhibited by AG1478. AG1478 induced cell cycle arrest in G1 phase, and the levels of protein p27 were significantly up-regulated. We concluded that inhibition of the EGFR signaling induced cell cycle arrest in G1 phase in CNE2 cells and p27 up-regulation was involved in this process. The EGFR kinase specific inhibitor is of potential to be developed into drugs for NPC treatment. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:27 / 32
页数:6
相关论文
共 20 条
[1]   GROWTH-FACTORS AND CANCER [J].
AARONSON, SA .
SCIENCE, 1991, 254 (5035) :1146-1153
[2]   Mechanism of activation of protein kinase B by insulin and IGF-1 [J].
Alessi, DR ;
Andjelkovic, M ;
Caudwell, B ;
Cron, P ;
Morrice, N ;
Cohen, P ;
Hemmings, BA .
EMBO JOURNAL, 1996, 15 (23) :6541-6551
[3]   Reversible G1 arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27KIP1 independent of MAPK activity [J].
Busse, D ;
Doughty, RS ;
Ramsey, TT ;
Russell, WE ;
Price, JO ;
Flanagan, WM ;
Shawver, LK ;
Arteaga, CL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (10) :6987-6995
[4]   RECEPTOR TYROSINE KINASES [J].
CADENA, DL ;
GILL, GN .
FASEB JOURNAL, 1992, 6 (06) :2332-2337
[5]  
Chan ATC, 1998, CANCER-AM CANCER SOC, V82, P1003, DOI 10.1002/(SICI)1097-0142(19980315)82:6<1003::AID-CNCR1>3.0.CO
[6]  
2-F
[7]   Downstream signalling events regulated by phosphatidylinositol 3-kinase activity [J].
Duronio, V ;
Scheid, MP ;
Ettinger, S .
CELLULAR SIGNALLING, 1998, 10 (04) :233-239
[8]   PREVALENCE OF ABERRANT EXPRESSION OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR IN HUMAN CANCERS [J].
GULLICK, WJ .
BRITISH MEDICAL BULLETIN, 1991, 47 (01) :87-98
[9]   A MUTANT EPIDERMAL GROWTH-FACTOR RECEPTOR WITH DEFECTIVE PROTEIN TYROSINE KINASE IS UNABLE TO STIMULATE PROTOONCOGENE EXPRESSION AND DNA-SYNTHESIS [J].
HONEGGER, AM ;
SZAPARY, D ;
SCHMIDT, A ;
LYALL, R ;
VANOBBERGHEN, E ;
DULL, TJ ;
ULLRICH, A ;
SCHLESSINGER, J .
MOLECULAR AND CELLULAR BIOLOGY, 1987, 7 (12) :4568-4571
[10]   Epidermal growth factor receptor efficiently activates mitogen-activated protein kinase in HeLa cells and Hep2 cells conditionally defective in clathrin-dependent endocytosis [J].
Johannessen, LE ;
Ringerike, T ;
Molnes, J ;
Madshus, IH .
EXPERIMENTAL CELL RESEARCH, 2000, 260 (01) :136-145